Compare Old Dominion Freight Line Inc (ODFL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Old Dominion Freight Line Inc vs BIO-TECHNE Corp — how do they compare? Old Dominion Freight Line Inc trades at $183.23 (market cap $37.68B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Old Dominion Freight Line Inc is far larger — about 3.3× BIO-TECHNE Corp's market cap, and Old Dominion Freight Line Inc pays the higher dividend (0.64%). Which is the better fit depends on your goals — on Pluang, investors hold Old Dominion Freight Line Inc for 76 Days and BIO-TECHNE Corp for 63 Days on average.
| ODFL | TECH | |
|---|---|---|
Market Cap | $37.68B | $11.36B |
Volume | 1,550,104 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $248.73 | $72.61 |
52-Week Low | $126.29 | $43.31 |
Typical Hold Time | 76 Days | 63 Days |
Enterprise Value | $37.42B | $11.39B |
Dividend Yield | 0.64% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Old Dominion Freight Line (ODFL) trades at $175.61, down 1.35% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.68 exceeding the $1.54 estimate. Revenue for 2025 was $5.50B, with a net income margin of 19.44%. A 4.9% general rate increase effective October 5, 2026, aims to support service investments amid cost pressures.
ODFL presents a mixed outlook; analyst consensus is a Buy with a $230.93 price target, implying significant upside, but technical indicators suggest near-term pressure. Risks include freight demand volatility and high valuation multiples. The stock's investment case hinges on execution of rate increases and sustained operational efficiency in a competitive trucking sector.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
